Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
1
17%
Ph phase_2
5
83%

Phase Distribution

1

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
5(83.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 6 finished

Non-Completion Rate

100.0%

6 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Terminated(6)

Detailed Status

Withdrawn6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (16.7%)
Phase 25 (83.3%)

Trials by Status

withdrawn6100%

Recent Activity

0 active trials
Showing 5 of 6
withdrawnphase_2

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

NCT00227773
withdrawnphase_2

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

NCT00253526
withdrawnphase_1

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

NCT00052403
withdrawnphase_2

S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

NCT00072540
withdrawnphase_2

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

NCT00112879
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00227773Phase 2

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Withdrawn
NCT00253526Phase 2

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Withdrawn
NCT00052403Phase 1

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

Withdrawn
NCT00072540Phase 2

S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

Withdrawn
NCT00112879Phase 2

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Withdrawn
NCT00025051Phase 2

Celecoxib in Preventing Skin Cancer

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
6